Neslusan C, et al. - The cost-effectiveness of canagliflozin 300 mg and dapagliflozin 10 mg was comparatively evaluated among type 2 diabetes mellitus (T2DM) patients who were inadequately controlled with metformin. When compared to dapagliflozin 10 mg, canagliflozin 300 mg was likely to provide better health outcomes at a lower overall cost in these patients.